Loading...

We've got a brand new version of Simply Wall St! Try it out

NeuroScientific Biopharmaceuticals

ASX:NSB
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NSB
ASX
A$18M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
NSB Share Price and Events
7 Day Returns
-4.1%
ASX:NSB
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
27%
ASX:NSB
50.9%
AU Biotechs
16.3%
AU Market
NSB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NeuroScientific Biopharmaceuticals (NSB) -4.1% -2.1% -2.1% 27% - -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • NSB underperformed the Biotechs industry which returned 50.9% over the past year.
  • NSB outperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

NSB Value

 Is NeuroScientific Biopharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NeuroScientific Biopharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is A$0.235.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NeuroScientific Biopharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NeuroScientific Biopharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:NSB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.02
ASX:NSB Share Price ** ASX (2019-11-17) in AUD A$0.24
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NeuroScientific Biopharmaceuticals.

ASX:NSB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:NSB Share Price ÷ EPS (both in AUD)

= 0.24 ÷ -0.02

-10.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeuroScientific Biopharmaceuticals is loss making, we can't compare its value to the Global Biotechs industry average.
  • NeuroScientific Biopharmaceuticals is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does NeuroScientific Biopharmaceuticals's expected growth come at a high price?
Raw Data
ASX:NSB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NeuroScientific Biopharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NeuroScientific Biopharmaceuticals's assets?
Raw Data
ASX:NSB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.07
ASX:NSB Share Price * ASX (2019-11-17) in AUD A$0.24
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:NSB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:NSB Share Price ÷ Book Value per Share (both in AUD)

= 0.24 ÷ 0.07

3.42x

* Primary Listing of NeuroScientific Biopharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeuroScientific Biopharmaceuticals is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess NeuroScientific Biopharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NeuroScientific Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NSB Future Performance

 How is NeuroScientific Biopharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroScientific Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NeuroScientific Biopharmaceuticals expected to grow at an attractive rate?
  • Unable to compare NeuroScientific Biopharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare NeuroScientific Biopharmaceuticals's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare NeuroScientific Biopharmaceuticals's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:NSB Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:NSB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:NSB Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -1 -2
2019-03-31 0 -1 -2
2018-12-31 0 -1 -1
2018-09-30 0 -1 -1
2018-06-30 0 0 -1
2018-03-31 0 0 -1
2017-12-31 0 0 0
2017-09-30 0 0 0
2017-06-30 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if NeuroScientific Biopharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if NeuroScientific Biopharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:NSB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from NeuroScientific Biopharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:NSB Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.02
2019-03-31 -0.03
2018-12-31 -0.03
2018-09-30 -0.03
2018-06-30 -0.03
2018-03-31 -0.02
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NeuroScientific Biopharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine NeuroScientific Biopharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. NeuroScientific Biopharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. NeuroScientific Biopharmaceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess NeuroScientific Biopharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NeuroScientific Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NSB Past Performance

  How has NeuroScientific Biopharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NeuroScientific Biopharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NeuroScientific Biopharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare NeuroScientific Biopharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NeuroScientific Biopharmaceuticals's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NeuroScientific Biopharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NeuroScientific Biopharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:NSB Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.03 -1.66 0.82 0.73
2019-03-31 0.03 -1.55 0.88 0.54
2018-12-31 0.03 -1.45 0.94 0.35
2018-09-30 0.03 -1.19 0.87 0.21
2018-06-30 0.03 -0.93 0.80 0.08
2018-03-31 0.03 -0.68 0.50 0.15
2017-12-31 0.04 -0.43 0.20 0.23
2017-09-30 0.04 -0.35 0.12 0.23
2017-06-30 0.04 -0.26 0.04 0.23
2016-06-30 0.12 -0.10 0.22

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NeuroScientific Biopharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NeuroScientific Biopharmaceuticals has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NeuroScientific Biopharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NeuroScientific Biopharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NeuroScientific Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NSB Health

 How is NeuroScientific Biopharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NeuroScientific Biopharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NeuroScientific Biopharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NeuroScientific Biopharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NeuroScientific Biopharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • NeuroScientific Biopharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NeuroScientific Biopharmaceuticals Company Filings, last reported 4 months ago.

ASX:NSB Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 5.06 0.00 4.61
2019-03-31 5.06 0.00 4.61
2018-12-31 5.81 0.00 5.08
2018-09-30 5.81 0.00 5.08
2018-06-30 0.73 0.00 0.10
2018-03-31 0.73 0.00 0.10
2017-12-31 0.21 0.08 0.07
2017-09-30 0.21 0.08 0.07
2017-06-30 0.54 0.00 0.13
2016-06-30
  • NeuroScientific Biopharmaceuticals has no debt.
  • NeuroScientific Biopharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NeuroScientific Biopharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • NeuroScientific Biopharmaceuticals has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 76.2% each year.
X
Financial health checks
We assess NeuroScientific Biopharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NeuroScientific Biopharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NSB Dividends

 What is NeuroScientific Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NeuroScientific Biopharmaceuticals dividends.
If you bought A$2,000 of NeuroScientific Biopharmaceuticals shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NeuroScientific Biopharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NeuroScientific Biopharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:NSB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NeuroScientific Biopharmaceuticals has not reported any payouts.
  • Unable to verify if NeuroScientific Biopharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NeuroScientific Biopharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NeuroScientific Biopharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NeuroScientific Biopharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NeuroScientific Biopharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NeuroScientific Biopharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NSB Management

 What is the CEO of NeuroScientific Biopharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Matthew Liddelow
COMPENSATION A$191,036
TENURE AS CEO 1.8 years
CEO Bio

Mr. Liddlelow serves as Managing Director, Chief Executive Officer & Director of NeuroScientific Biopharmaceuticals Limited. Mr Liddelow has over 12 years’ experience in the commercialisation of biotechnology, medical devices and pharmaceuticals. Mr Liddelow has been involved in a number of start-up companies, including medical device company Medevco Pty Ltd, which was acquired by Allied Healthcare Group Ltd (now Ademus Ltd). While employed by multinational pharmaceutical company Astra Zeneca, Me Liddelow gained first-hand experience in the development, marketing and product launch of cardio vascular and respiratory related medications. In 2014, Mr Liddelow found Enhanced Biomedical Pty Ltd of which he was Managing Director.

CEO Compensation
  • Matthew's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Matthew's remuneration is lower than average for companies of similar size in Australia.
Management Team

Matthew Liddelow

TITLE
MD, CEO & Director
COMPENSATION
A$191K
TENURE
1.8 yrs

Thomas Spencer

TITLE
Company Secretary & CFO
COMPENSATION
A$42K

Anton Uvarov

TITLE
Executive Director
COMPENSATION
A$104K
Board of Directors

Brian Leedman

TITLE
Non-Executive Chairman
COMPENSATION
A$100K

Matthew Liddelow

TITLE
MD, CEO & Director
COMPENSATION
A$191K
TENURE
1.8 yrs

Anton Uvarov

TITLE
Executive Director
COMPENSATION
A$104K
TENURE
2.2 yrs

Stephen Quantrill

TITLE
Non-Executive Director
COMPENSATION
A$42K
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
23. Nov 18 Buy Tashtech Pty Ltd. Company 22. Nov 18 22. Nov 18 91,875 A$0.19 A$17,417
23. Nov 18 Buy Brian Leedman Individual 22. Nov 18 22. Nov 18 88,130 A$0.16 A$14,132
X
Management checks
We assess NeuroScientific Biopharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NeuroScientific Biopharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NSB News

Simply Wall St News

Do Directors Own NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) Shares?

See our latest analysis for NeuroScientific Biopharmaceuticals ASX:NSB Ownership Summary, May 29th 2019 What Does The Institutional Ownership Tell Us About NeuroScientific Biopharmaceuticals? … We can see that NeuroScientific Biopharmaceuticals does have institutional investors; and they hold 7.0% of the stock. … Insider Ownership Of NeuroScientific Biopharmaceuticals The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Is NeuroScientific Biopharmaceuticals Ltd's (ASX:NSB) Balance Sheet Strong Enough To Weather A Storm?

The direct benefit for NeuroScientific Biopharmaceuticals Ltd (ASX:NSB), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is NSB right in choosing financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Do Directors Own NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) Shares?

A look at the shareholders of NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) can tell us which group is most powerful. … NeuroScientific Biopharmaceuticals is a smaller company with a market capitalization of AU$11m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

What does NeuroScientific Biopharmaceuticals Ltd's (ASX:NSB) Balance Sheet Tell Us About Its Future?

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is financial flexibility worth the lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

NSB Company Info

Description

NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies. The company’s lead drug candidates include EmtinB therapeutic peptide developed as treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Nedlands, Australia.

Details
Name: NeuroScientific Biopharmaceuticals Limited
NSB
Exchange: ASX
Founded: 2002
A$17,632,931
78,368,584
Website: http://www.neuroscientific.com
Address: NeuroScientific Biopharmaceuticals Limited
45 Stirling Highway,
Level 1,
Nedlands,
Western Australia, 6009,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX NSB Ordinary Shares Australian Securities Exchange AU AUD 27. Jul 2018
CHIA NSB Ordinary Shares Chi-X Australia AU AUD 27. Jul 2018
Number of employees
Current staff
Staff numbers
0
NeuroScientific Biopharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:47
End of day share price update: 2019/11/17 00:00
Last earnings filing: 2019/08/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.